We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Laser-Based Imaging Technique Enables Much Faster Tissue Diagnosis during Tumor Surgery

By LabMedica International staff writers
Posted on 26 Oct 2023
Print article
Image: A new AI technique enables rapid digital tissue analysis for brain tumor surgery (Photo courtesy of Medical University Vienna)
Image: A new AI technique enables rapid digital tissue analysis for brain tumor surgery (Photo courtesy of Medical University Vienna)

The central nervous system can have around 120 different kinds of tumors, and the first step in treating them generally involves surgery along with acquiring histological samples. During this procedure, a small part of the tumor is excised and a histological frozen section is readied in the neuropathology department to better understand the tumor's features. Now, a newly developed laser-based imaging method allows neuropathologists to generate a report in just a matter of minutes.

Surgeons at Medical University Vienna (Vienna, Austria) have started employing this novel laser-based imaging method that considerably speeds up tissue diagnosis during tumor surgeries. Using Stimulated Raman Histology (SRH), a digital cross-section of the tissue can be instantly created right in the surgical suite, enabling a diagnosis within just a few minutes. In comparison, the standard method involving tissue transportation, manual preparation, and analysis usually takes around 30 minutes on an international average.

One of the advantages of this technique is that since the tissue is examined in its natural, untreated form, it remains fully available for any subsequent, more in-depth diagnostic tests. If SRH detects diagnostic tumor tissue, needle biopsies can also be concluded much more quickly. These procedures are not applicable just to brain tumors but can also be utilized for confirming diagnoses of other neurological conditions like blood vessel inflammatory diseases and demyelinating lesions. Initially developed in the United States, the SRH method was first adopted in Europe at the Department of Neurosurgery of MedUni Vienna and University Hospital Vienna, led by Georg Widhalm. A research study at MedUni Vienna showed a 99% correlation between digital histology and conventional frozen section.

"The new technology enables surgeons to make faster decisions regarding the optimal surgical strategy in the operating room, which significantly reduces the time in the operating room for patients. In addition, the safety of the procedure is also increased," said Georg Widhalm.

Related Links:
Medical University Vienna 

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Dengue Virus Test
LINEAR Dengue-CHIK

Print article
77 ELEKTRONIKA

Channels

Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more

Molecular Diagnostics

view channel
Image: Researchers have found the first evidence of testing for the alpha-synuclein protein in blood samples via seed amplification assay (Photo courtesy of Shutterstock)

Blood Test to Detect Alpha-Synuclein Protein Could Revolutionize Parkinson's Disease Diagnostics

Currently, Parkinson's disease (PD) is identified through clinical diagnosis, typically at a later stage in the disease's progression. There is a pressing need for an objective and quantifiable biomarker... Read more

Hematology

view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more

Immunology

view channel
Image: The blood test measures lymphocytes  to guide the use of multiple myeloma immunotherapy (Photo courtesy of 123RF)

Simple Blood Test Identifies Multiple Myeloma Patients Likely to Benefit from CAR-T Immunotherapy

Multiple myeloma, a type of blood cancer originating from plasma cells in the bone marrow, sees almost all patients experiencing a relapse at some stage. This means that the cancer returns even after initially... Read more

Microbiology

view channel
Image: Ultra-Rapid Antimicrobial Susceptibility Testing (uRAST) revolutionizing traditional antibiotic susceptibility testing (Photo courtesy of Seoul National University)

Ultra-Rapid Culture-Free Sepsis Test Reduces Testing Time from Days to Hours

Sepsis, a critical emergency condition, results from an overactive inflammatory response to pathogens like bacteria or fungi in the blood, leading to organ damage and the possibility of sudden death.... Read more

Pathology

view channel
Image: The AI model can distinguish different stages of DCIS from inexpensive and readily available breast tissue images (Photo courtesy of David A. Litman/Shutterstock)

AI Model Identifies Breast Tumor Stages Likely To Progress to Invasive Cancer

Ductal carcinoma in situ (DCIS) is a non-invasive type of tumor that can sometimes progress to a more lethal form of breast cancer and represents about 25% of all breast cancer cases. Between 30% and 50%... Read more

Industry

view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.